[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months
Roche reported strong Group sales growth of 6% (CER) to CHF 45.0 billion in the first nine months of 2024, with a notable 9% increase in Q3. The Pharmaceuticals Division saw 7% growth to CHF 34.3 billion, driven by newer medicines like Vabysmo, Phesgo, and Ocrevus. The Diagnostics Division grew 5% to CHF 10.7 billion.
Key achievements include US approvals for Itovebi (breast cancer), Ocrevus Zunovo (multiple sclerosis), and Tecentriq Hybreza (cancer), plus EU approvals for Vabysmo (eye disease) and PiaSky (blood condition). Positive phase III data was reported for several medicines including Gazyva/Gazyvaro and Xofluza.
Roche ha riportato una forte crescita delle vendite del Gruppo del 6% (CER) a CHF 45,0 miliardi nei primi nove mesi del 2024, con un notevole incremento del 9% nel terzo trimestre. La Divisione Farmaceutica ha registrato una crescita del 7% a CHF 34,3 miliardi, sostenuta da nuovi farmaci come Vabysmo, Phesgo e Ocrevus. La Divisione Diagnostica è cresciuta del 5% a CHF 10,7 miliardi.
I risultati chiave includono le approvazioni negli Stati Uniti per Itovebi (cancro al seno), Ocrevus Zunovo (sclerosi multipla) e Tecentriq Hybreza (cancro), oltre alle approvazioni UE per Vabysmo (malattia oculare) e PiaSky (condizione del sangue). Sono stati riportati dati positivi di fase III per diversi medicinali, tra cui Gazyva/Gazyvaro e Xofluza.
Roche informó un fuerte crecimiento en las ventas del Grupo del 6% (CER) a CHF 45.0 mil millones en los primeros nueve meses de 2024, con un notable aumento del 9% en el tercer trimestre. La División Farmacéutica experimentó un crecimiento del 7% hasta CHF 34.3 mil millones, impulsada por nuevos medicamentos como Vabysmo, Phesgo y Ocrevus. La División de Diagnósticos creció un 5% hasta CHF 10.7 mil millones.
Los logros clave incluyen las aprobaciones en EE.UU. para Itovebi (cáncer de mama), Ocrevus Zunovo (esclerosis múltiple) y Tecentriq Hybreza (cáncer), además de aprobaciones en la UE para Vabysmo (enfermedad ocular) y PiaSky (condición sanguínea). Se reportaron datos positivos de fase III para varios medicamentos, incluyendo Gazyva/Gazyvaro y Xofluza.
로슈는 2024년 첫 9개월 동안 그룹 매출이 6% (CER) 성장하여 450억 스위스 프랑에 달했다고 보고했으며, 3분기에는 9%의 두드러진 증가가 있었습니다. 제약 부문은 Vabysmo, Phesgo 및 Ocrevus와 같은 신약 덕분에 7% 성장하여 343억 스위스 프랑에 도달했습니다. 진단 부문은 5% 성장하여 107억 스위스 프랑에 도달했습니다.
주요 성과로는 유방암에 대한 Itovebi, 다발성 경화증에 대한 Ocrevus Zunovo 및 암에 대한 Tecentriq Hybreza의 미국 승인과, 눈 질환에 대한 Vabysmo 및 혈액 질환에 대한 PiaSky에 대한 EU 승인이 포함됩니다. Gazyva/Gazyvaro 및 Xofluza를 포함한 여러 약물의 3상 긍정 데이터가 보고되었습니다.
Roche a annoncé une forte croissance des ventes du Groupe de 6% (CER) à 45,0 milliards de CHF au cours des neuf premiers mois de 2024, avec une augmentation notable de 9% au troisième trimestre. La Division Pharmaceutique a enregistré une croissance de 7% à 34,3 milliards de CHF, soutenue par de nouveaux médicaments tels que Vabysmo, Phesgo et Ocrevus. La Division Diagnostique a crû de 5% à 10,7 milliards de CHF.
Parmi les réalisations clés, on trouve les approbations aux États-Unis pour Itovebi (cancer du sein), Ocrevus Zunovo (sclérose en plaques) et Tecentriq Hybreza (cancer), ainsi que les approbations dans l'UE pour Vabysmo (maladie oculaire) et PiaSky (maladie du sang). Des données positives de phase III ont été rapportées pour plusieurs médicaments, dont Gazyva/Gazyvaro et Xofluza.
Roche meldete ein starkes Umsatzwachstum von 6% (CER) auf 45,0 Milliarden CHF in den ersten neun Monaten des Jahres 2024, mit einem bemerkenswerten Anstieg von 9% im dritten Quartal. Die Pharmazeutische Abteilung verzeichnete ein Wachstum von 7% auf 34,3 Milliarden CHF, angetrieben durch neuere Medikamente wie Vabysmo, Phesgo und Ocrevus. Die Diagnoseabteilung wuchs um 5% auf 10,7 Milliarden CHF.
Zu den wichtigsten Erfolgen gehören die US-Zulassungen für Itovebi (Brustkrebs), Ocrevus Zunovo (Multiple Sklerose) und Tecentriq Hybreza (Krebs) sowie die EU-Zulassungen für Vabysmo (Augenerkrankung) und PiaSky (Blutkrankheit). Positive Daten aus Phase-III-Studien wurden für mehrere Medikamente, darunter Gazyva/Gazyvaro und Xofluza, berichtet.
- Strong Q3 sales growth of 9% (CER)
- Base business growth of 8% excluding COVID-19 products
- Pharmaceuticals Division sales up 7% to CHF 34.3 billion
- Five major regulatory approvals in Q3
- Vabysmo sales reached CHF 2.8 billion with strong growth
- International region sales surged 19%
- Japan sales declined 21% due to lower Ronapreve sales
- COVID-19 test sales dropped from CHF 0.4B to CHF 0.1B
- Continued biosimilar erosion affecting Avastin, Herceptin, and MabThera/Rituxan sales
- Group sales grew by
6% 1 at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by8% - In the third quarter, Group sales rose by
9% (6% in CHF), as they did in the second quarter - Pharmaceuticals Division sales rose by
7% in the first nine months; the strong growth of9% in the base business2 was driven by continued high demand for our newer medicines to treat severe diseases; Vabysmo (serious eye diseases), Phesgo (breast cancer) and Ocrevus (multiple sclerosis) were major growth drivers - Diagnostics Division sales increased by
5% in the first nine months, while the base business2 grew by8% due to higher demand for immunodiagnostic, pathology and molecular solutions - Highlights:
- US approval for Itovebi (inavolisib) for breast cancer, Ocrevus Zunovo subcutaneous injection for multiple sclerosis and Tecentriq Hybreza subcutaneous formulation for various types of cancer
- EU approval for Vabysmo for retinal vein occlusion (RVO), a serious eye disease, and PiaSky for paroxysmal nocturnal haemoglobinuria (PNH), a rare life-threatening blood condition
- Positive phase III data for Gazyva/Gazyvaro (lupus nephritis, a kidney disease), Xofluza (influenza) and Tecentriq (lung cancer). New positive phase II data for fenebrutinib (multiple sclerosis), and new positive long-term data for Evrysdi (spinal muscular atrophy)
- Acquired AntlerA Therapeutics for a novel target in ophthalmology, and signed agreement for the acquisition of two next-generation CDK inhibitor drugs targeting breast cancer from Regor Pharmaceuticals
- Closing of acquisition of LumiraDx’s point-of-care technology to expand access to diagnostic testing in primary care and low- and middle-income countries
- Launch of the cobas Respiratory flex test, the first to use our new Temperature-Activated Generation of Signal (TAGS) technology
- WHO endorsement for CINtec PLUS testing for cervical cancer prevention
- Outlook for 2024 confirmed
Roche CEO Thomas Schinecker: “Our strong growth momentum continued in the third quarter, reflecting the high demand for our innovative medicines and diagnostic solutions and their positive impact on patients’ lives around the world.
We made significant progress in our pharmaceuticals portfolio in the last quarter with five important regulatory approvals for our medicines, three positive phase III read-outs, and two acquisitions to strengthen our oncology and ophthalmology pipelines.
Itovebi (inavolisib) recently received US approval based on clinical data demonstrating a reduction of more than
We confirm our outlook for 2024.”
Sales | CHF millions | As % of sales | % change | |||
January‒September | 2024 | 2023 | 2024 | 2023 | At CER | In CHF |
Group | 44,984 | 44,053 | 100.0 | 100.0 | 6 | 2 |
Pharmaceuticals Division | 34,257 | 33,372 | 76.2 | 75.8 | 7 | 3 |
United States | 18,166 | 17,430 | 40.4 | 39.6 | 7 | 4 |
Europe | 6,613 | 6,259 | 14.7 | 14.2 | 7 | 6 |
Japan | 2,083 | 2,937 | 4.6 | 6.7 | -21 | -29 |
International* | 7,395 | 6,746 | 16.5 | 15.3 | 19 | 10 |
Diagnostics Division | 10,727 | 10,681 | 23.8 | 24.2 | 5 | 0 |
All figures shown in the table were restated to reflect the shift of the Foundation Medicine (FMI) business from the Pharmaceuticals Division to the Diagnostics Division.
*Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others
Outlook for 2024 confirmed
Roche expects an increase in Group sales in the mid single digit range (CER).
Core earnings per share are targeted to grow in the high single digit range (CER), excluding the impact from the resolution of tax disputes in 2023.
Roche expects to further increase its dividend in Swiss francs.
Group sales
In the first nine months of 2024, Group sales increased by
The appreciation of the Swiss franc against most currencies had an adverse impact on the sales reported in Swiss francs compared to constant exchange rates.
The Pharmaceuticals Division sales increased by
These five medicines together generated total sales of CHF 13.2 billion, an increase of CHF 2.7 billion (CER) from the first nine months of 2023.
The eye medicine Vabysmo, launched in early 2022, continues to be a major growth driver, generating sales of CHF 2.8 billion on growing demand in all regions.
Sales of Avastin (various types of cancer), Herceptin (breast and gastric cancer) and MabThera/Rituxan (blood cancer, rheumatoid arthritis) decreased by a combined CHF 0.5 billion as the impact of biosimilar competition slowed further. Sales of the COVID-19 medicine Ronapreve were negligible compared with CHF 0.5 billion in the first nine months of 2023.
In the United States, sales grew by
In Europe, sales rose by
Sales in Japan were down
Sales in the International region surged by
The Diagnostics Division sales increased by
Sales growth was reported across regions, with the Europe, Middle East and Africa (EMEA) region growing by
Pharmaceuticals: key developments
Compound | Milestone |
Regulatory | |
Itovebi (inavolisib) Breast cancer | FDA approves Itovebi, a targeted treatment for advanced hormone receptor (HR)-positive, HER2-negative breast cancer with a PIK3CA mutation
More information: Media Release, 11 October 2024 |
Ocrevus Zunovo Multiple sclerosis | FDA approves Ocrevus Zunovo as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
More information: Media Release, 16 September 2024 |
Tecentriq Hybreza Various types of cancer | FDA approves Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
More information: Media Release, 13 September 2024 |
PiaSky Rare blood disease | PiaSky approved in the EU as the first monthly subcutaneous treatment for people with paroxysmal nocturnal haemoglobinuria (PNH)
More information: Media Release, 27 August 2024 |
Vabysmo Severe eye diseases | European Commission approves Vabysmo for treatment of retinal vein occlusion (RVO)
More information: Media Release, 30 July 2024 |
Phase III, pivotal and other key readouts | |
Evrysdi Spinal muscular atrophy | Majority of children with spinal muscular atrophy (SMA) treated with Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
More information: Media Release, 14 October 2024 |
Gazyva/ Gazyvaro Kidney disease | Positive phase III results for Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
More information: Media Release, 26 September 2024 |
Xofluza Influenza | Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
More information: Media Release, 19 September 2024 |
Fenebrutinib Multiple sclerosis | Fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
More information: Media Release, 4 September 2024 |
Susvimo Severe eye disease | New data for Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
More information: Media Release, 18 July 2024 |
Other | |
Pharma Research and Early Development Center | Roche opens Pharma Research and Early Development Center in Basel to accelerate scientific innovation
More information: Media Release, 10 September 2024 |
Pharmaceuticals sales
Sales | CHF millions | As % of sales | % change | |||
January–September | 2024 | 2023 | 2024 | 2023 | At CER | In CHF |
Pharmaceuticals Division | 34,257 | 33,372 | 100.0 | 100.0 | 7 | 3 |
United States | 18,166 | 17,430 | 53.0 | 52.2 | 7 | 4 |
Europe | 6,613 | 6,259 | 19.3 | 18.8 | 7 | 6 |
Japan | 2,083 | 2,937 | 6.1 | 8.8 | -21 | -29 |
International* | 7,395 | 6,746 | 21.6 | 20.2 | 19 | 10 |
All figures shown in the table were restated to reflect the shift of the Foundation Medicine (FMI) business from the Pharmaceuticals Division to the Diagnostics Division.
* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others
Top-selling medicines | Total | United States | Europe | Japan | International | |||||
CHF m | % | CHF m | % | CHF m | % | CHF m | % | CHF m | % | |
Ocrevus Multiple sclerosis | 5,056 | 9 | 3,640 | 7 | 961 | 11 | - | - | 455 | 26 |
Hemlibra Haemophilia A | 3,280 | 10 | 1,906 | 5 | 690 | 10 | 259 | 4 | 425 | 42 |
Vabysmo Eye diseases (nAMD, DME, RVO) | 2,816 | 79 | 2,146 | 67 | 454 | 148 | 86 | 37 | 130 | 256 |
Perjeta3 Breast cancer | 2,809 | -1 | 1,029 | -4 | 502 | -17 | 92 | -36 | 1,186 | 17 |
Tecentriq Cancer immunotherapy | 2,703 | 1 | 1,325 | -8 | 649 | 5 | 277 | -1 | 452 | 32 |
Actemra/RoActemra3 RA, COVID-19 | 1,948 | 5 | 949 | 11 | 508 | -11 | 225 | 9 | 266 | 17 |
Xolair3 Asthma | 1,737 | 11 | 1,737 | 11 | - | - | - | - | - | - |
Kadcyla3 Breast cancer | 1,494 | 6 | 574 | 4 | 428 | -2 | 71 | 4 | 421 | 22 |
Evrysdi Spinal muscular atrophy | 1,246 | 21 | 429 | 15 | 435 | 18 | 66 | 10 | 316 | 35 |
Phesgo Breast cancer | 1,244 | 58 | 404 | 29 | 543 | 44 | 88 | - | 209 | 104 |
Alecensa Lung cancer | 1,151 | 7 | 372 | 12 | 217 | 1 | 144 | 3 | 418 | 8 |
Herceptin3 Breast and gastric cancer | 1,063 | -11 | 201 | -20 | 227 | -15 | 11 | -48 | 624 | -5 |
MabThera/Rituxan3 Blood cancer, RA | 1,023 | -16 | 615 | -17 | 109 | -21 | 12 | -26 | 287 | -10 |
Avastin 3 Various cancer types | 943 | -17 | 289 | -20 | 63 | -17 | 149 | -33 | 442 | -8 |
Activase/TNKase3 Cardiac diseases | 895 | 2 | 850 | 1 | - | - | - | - | 45 | 5 |
Polivy Blood cancer | 817 | 41 | 410 | 83 | 142 | 6 | 143 | -4 | 122 | 79 |
Gazyva/Gazyvaro3 Blood cancer | 670 | 13 | 333 | 15 | 185 | 8 | 21 | -16 | 131 | 21 |
Pulmozyme3 Cystic fibrosis | 329 | 0 | 213 | -5 | 55 | -3 | 1 | 17 | 60 | 23 |
Mircera3 Anaemia related to kidney disease | 304 | -1 | - | - | 31 | -6 | 28 | -23 | 245 | 4 |
CellCept3 Immunosuppressant | 283 | 1 | 17 | -21 | 81 | -13 | 27 | -9 | 158 | 17 |
DME: diabetic macular edema / nAMD: neovascular or ‘wet’ age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis
Diagnostics: key developments
Product | Milestone |
VENTANA CLDN18 assay Gastric or gastro-oesophageal junction cancer | Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastro-oesophageal junction cancer eligible for targeted treatment with VYLOY
More information: Media Release, 10 October 2024 |
cobas Respiratory flex test Respiratory illnesses | Roche launches the first test to use its breakthrough TAGS technology for high-throughput, simultaneous detection of 12 respiratory viruses
More information: Media Release, 24 September 2024 |
CINtec PLUS Cervical cancer | WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
More information: Media Release, 23 September 2024 |
cobas MPXV test, LightMix Mpox | Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak
More information: Media Release, 20 August 2024 |
LumiraDx | Roche closes acquisition of LumiraDx’s point-of-care technology to expand access to diagnostic testing in primary care
More information: Media Release, 29 July 2024 |
Diagnostics sales
Sales | CHF millions | As % of sales | % change | |||
January–September | 2024 | 2023 | 2024 | 2023 | At CER | In CHF |
Diagnostics Division | 10,727 | 10,681 | 100.0 | 100.0 | 5 | 0 |
Customer Areas4 | ||||||
Core Lab | 6,052 | 5,836 | 56.4 | 54.6 | 9 | 4 |
Molecular Lab5 | 1,903 | 1,897 | 17.7 | 17.8 | 4 | 0 |
Near Patient Care6 | 1,616 | 1,902 | 15.1 | 17.8 | -10 | -15 |
Pathology Lab | 1,156 | 1,046 | 10.8 | 9.8 | 15 | 11 |
Regions | ||||||
Europe, Middle East and Africa | 3,589 | 3,569 | 33.5 | 33.4 | 5 | 1 |
North America5 | 3,222 | 3,103 | 30.0 | 29.1 | 6 | 4 |
Asia-Pacific | 3,146 | 3,263 | 29.3 | 30.5 | 2 | -4 |
Latin America | 770 | 746 | 7.2 | 7.0 | 18 | 3 |
More information on Roche sales in the first nine months of 2024:
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in diagnostics and pharmaceuticals with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
[1] Unless otherwise stated, all growth rates and comparisons to the previous year in this document are at constant exchange rates (CER: average rates 2023) and all total figures quoted are reported in CHF.
[2] Pharmaceuticals Division base business: excluding COVID-19 medicine Ronapreve.
Diagnostics Division base business: excluding COVID-19-related products.
[3] Products launched before 2015.
[4] Core Lab: diagnostics solutions in the areas of immunoassays, clinical chemistry and CustomBiotech.
Molecular Lab: diagnostics solutions for pathogen detection and monitoring, donor screening, sexual health and genomics, genomic tumour profiling.
Near Patient Care: diagnostics solutions in emergency rooms, medical practices and directly with patients, including integrated personalised diabetes management.
Pathology Lab: diagnostics solutions for tissue biopsies and companion diagnostics.
[5] Sales in the Molecular Lab customer area include sales from the Foundation Medicine business, which moved under the responsibility of the Diagnostics Division from the Pharmaceuticals Division effective 1 January 2024. The comparative information for 2023 has been restated accordingly.
[6] Sales in the new Near Patient Care customer area include sales from Diabetes Care and the Point of Care business, both previously shown as separate customer areas. The comparative information for 2023 has been restated accordingly.
Cautionary statement regarding forward-looking statements
This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95 |
Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
Nina Mählitz Phone: +41 79 327 54 74 | Kirti Pandey Phone: +49 172 6367262 |
Yvette Petillon Phone: +41 79 961 92 50 | Dr Rebekka Schnell Phone: +41 79 205 27 03 |
Roche Investor Relations
Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Attachments
FAQ
What was Roche's (RHHBY) sales growth in Q3 2024?
How much did Vabysmo sales generate for Roche (RHHBY) in the first nine months of 2024?
What was Roche's (RHHBY) Pharmaceuticals Division sales growth in the first nine months of 2024?